Spenser Karr

Spenser Karr

Associate
Philadelphia

Email [email protected]​hoganlovells.com

Phone +1 267-938-7117

Fax +1 267 675 4601

Practice groupCorporate & Finance

Spenser Karr advises businesses in a variety of fundamental transactions and on day-to-day corporate legal matters. He works closely with his clients to delve into the details of their businesses and deliver practical advice, anticipating issues and avoiding roadblocks that might arise in a deal.

Spenser focuses on U.S. and international business transactions, including mergers and acquisitions, capital raises, private equity and venture capital investments and commercial transactions. Spenser's experience spans multiple industries, especially in the life sciences sector, and includes work with companies at all stages in their life cycle, from mature public companies to startups.

Education and admissions

Education

Juris Doctor, Temple University School of Law, summa cum laude, 2018

MA History, Tulane University, 2012

BA in History, Tulane University, cum laude, 2011

Bar admissions and qualifications

Pennsylvania

Representative experience

Represented Tenable Holdings, Inc. (Nasdaq: TENB), a cybersecurity provider, in its $160 million acquisition of Accurics, Inc., a pioneer in developing cloud-native security.

Represented Medical Outcomes Research Analytics in its merger with Helix Technologies, Inc., and the formation of the successor entity, Forian, Inc. (Nasdaq: FORA). *

Represented a leading global financial institution in its investment in a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines. *

Represented a leading global financial institution in its investment in a biopharmaceutical company specializing in heart disease treatment. *

Represented Tissue Analytics in its sale to Net Health, a provider of cloud-based EHR software for specialized care settings. *

Represented Texas Hospice Holdings, LLC, a multi-state hospice facility operator, in connection with the sale of all of its outstanding equity to Amedisys Inc., a publicly-held hospice company. *

Represented a biomedical marketing company in its negotiations of various contracts with major pharmaceutical companies. *

Represented a leading pharmacy provider to long-term care and post-acute care facilities in the acquisition of long-term care pharmacies located throughout the United States. *

Represented a leading pharmacy provider in various operational and corporate governance matters. *

Represented a pharmaceutical company developing injectable products for the treatment of allergic reactions in its acquisition by a developer of specialty pharmaceutical products. *

Represented a biomedical device start-up company in the negotiation of a term credit facility. *

Represented a biomedical device start-up company in the raise of Series B funding. *

Represented a clinical stage biopharmaceutical company in the negotiation of clinical trial agreements with multiple research and educational institutions. *

Represented leading medical cannabis operator in complicated opportunity zone investment opportunity, including fund raising, corporate governance matters, and real estate acquisition. *

Represented a clinical-trial stage U.S.-based developer of medical devices in its sale to a publicly-traded, global health technology company. *

Represented DuPont (NYSE: DD) in its $110 million acquisition of Evoqua’s Memcor business, which includes ultrafiltration and membrane bio-filtration technologies. *

Represented Pennsylvania Machine Works LLC, a leader in the forged pressure fitting industry, in connection with the multimillion-dollar sale of all of its outstanding equity. *

Represented financial technology company in a minority investment transaction involving complex structure and resolution of minority-shareholder issues. *

Represented a leading global financial institution in its investment in a leading fast-casual restaurant chain. *

Regularly represents the national non-profit veterans organization, Folds of Honor, in its formation of local chapters. *

Represented Emily’s Entourage, a non-profit organization focused on rare mutations of cystic fibrosis, in their partnership with a leading clinical trial organization. *

*Matter handled prior to joining Hogan Lovells.